Sandy Chevrier
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Sandy Chevrier has a total of 50 co-authors. Here are the top co-authors by number of shared publications:
- Romain Boidot
Centre Georges-François Leclerc, Université Bourgogne Europe, Unicancer, Molecular Biology Unit, Dijon, France
32 shared publications - Olivier Adotévi
Université Marie et Louis Pasteur, EFS, INSERM, UMR RIGHT, Besançon 25000, France; Department of Medical Oncology, University Hospital of Besançon, Besançon 25000, France
27 shared publications - Corentin Richard
Georges-François Leclerc Cancer Center 1 Université Bourgogne Europe UNICANCER, Unit of Molecular Biology, Department of Biology and Pathology of Cancer, ICMUB UMR CNRS 6302, Dijon, France
19 shared publications - François Ghiringhelli
Department of Medical Oncology, Centre Georges François Leclerc, Dijon, France
19 shared publications - Aurelien Marabelle
University of Paris Saclay, Gustave Roussy Cancer Center, Villejuif, France
14 shared publications - Diane Damotte
Université Paris Cité, APHP
14 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S2 from Impact of scFv on Functionality and Safety of Third-Generation CD123 CAR T Cells
Supplementary Figure S2: Characterization of CD123 CAR-T.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Impact of scFv on Functionality and Safety of Third-Generation CD123 CAR T Cells
Supplementary Figure S2: Characterization of CD123 CAR-T.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S1 from Impact of scFv on Functionality and Safety of Third-Generation CD123 CAR T Cells
Supplementary Figure S1: Design of five CD123 CAR-T constructs.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Impact of scFv on Functionality and Safety of Third-Generation CD123 CAR T Cells
Supplementary Figure S1: Design of five CD123 CAR-T constructs.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S4 from Impact of scFv on Functionality and Safety of Third-Generation CD123 CAR T Cells
Supplementary Figure S4 Effect of CD123 CAR-T on humanized mouse model, NSG-SGM3.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from Impact of scFv on Functionality and Safety of Third-Generation CD123 CAR T Cells
Supplementary Figure S4 Effect of CD123 CAR-T on humanized mouse model, NSG-SGM3.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S3 from Impact of scFv on Functionality and Safety of Third-Generation CD123 CAR T Cells
Supplementary Figure S3: Effect of CD123 CAR-T on human Hematopoietic stem cell.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from Impact of scFv on Functionality and Safety of Third-Generation CD123 CAR T Cells
Supplementary Figure S3: Effect of CD123 CAR-T on human Hematopoietic stem cell.
- Open Access
- 1 April 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Circulating Transcriptome Analysis Finds Gene Signatures and Immune Cell Activation and Abundance Predict Response to Immunotherapy in Bladder Cancer
Supplementary Figure S4: A. Venn diagram showed that among the 112 genes higher expressed in patients with shorter PFS, 15 overlapped with genes also higher expressed in patients without DCB, 7 were specific to absence of DCB, and 97 were specific to shorter PFS. B. Venn diagram showed that among the 37 genes higher expressed in patients with longer PFS, 14 overlapped with genes also higher in patients with DCB, 35 were specific to DCB, and 23 were specific to longer PFS.
- 1 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from Circulating Transcriptome Analysis Finds Gene Signatures and Immune Cell Activation and Abundance Predict Response to Immunotherapy in Bladder Cancer
Supplementary Figure S4: A. Venn diagram showed that among the 112 genes higher expressed in patients with shorter PFS, 15 overlapped with genes also higher expressed in patients without DCB, 7 were specific to absence of DCB, and 97 were specific to shorter PFS. B. Venn diagram showed that among the 37 genes higher expressed in patients with longer PFS, 14 overlapped with genes also higher in patients with DCB, 35 were specific to DCB, and 23 were specific to longer PFS.
- Open Access
- 1 April 2026
- Published by American Association for Cancer Research (AACR)
Data from Circulating Transcriptome Analysis Finds Gene Signatures and Immune Cell Activation and Abundance Predict Response to Immunotherapy in Bladder Cancer
Purpose:Immune checkpoint blockers (ICB) have revolutionized oncology by achieving durable tumor responses in advanced cancers. Nevertheless, currently approved biomarkers (PD-L1, microsatellite instability, and tumor mutational burden) have suboptimal positive and negative predictive values for tumor response and survival.Experimental Design:We aimed to assess the value of RNA sequencing from whole blood to predict responses to ICB. We performed total paired-end RNA sequencing at 20 million reads and analyzed differential gene expression, signaling pathway activation, and immune cell abundances according to cancer outcomes. The analysis was conducted on baseline frozen whole blood samples from 164 patients prospectively enrolled in the IOPREDI study.Results:We found that some immune-related genes and signaling pathways were highly expressed in patients who achieved a durable clinical benefit. Furthermore, analyses of both progression-free survival (PFS) and overall survival (OS) confirmed significantly higher expression levels of immune-related signaling pathways in long-term survivors. Gene expression signatures capable of classifying patients based on clinical response or PFS were also identified. Interestingly, deconvolution analysis revealed a significant higher abundance of resting NK cells in patients with prolonged PFS or OS, in contrast to other cytotoxic cell types. Finally, high expression of the CST7 gene and increased abundance of naïve B lymphocytes were associated with immune-related adverse events (irAE).Conclusions:Total RNA sequencing from whole blood provides high-quality data to predict clinical response, survival, and occurrence of irAE. The use of this type of sample before immune checkpoint blockage could improve treatment efficacy and irAE management.
- 1 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Circulating Transcriptome Analysis Finds Gene Signatures and Immune Cell Activation and Abundance Predict Response to Immunotherapy in Bladder Cancer
Purpose:Immune checkpoint blockers (ICB) have revolutionized oncology by achieving durable tumor responses in advanced cancers. Nevertheless, currently approved biomarkers (PD-L1, microsatellite instability, and tumor mutational burden) have suboptimal positive and negative predictive values for tumor response and survival.Experimental Design:We aimed to assess the value of RNA sequencing from whole blood to predict responses to ICB. We performed total paired-end RNA sequencing at 20 million reads and analyzed differential gene expression, signaling pathway activation, and immune cell abundances according to cancer outcomes. The analysis was conducted on baseline frozen whole blood samples from 164 patients prospectively enrolled in the IOPREDI study.Results:We found that some immune-related genes and signaling pathways were highly expressed in patients who achieved a durable clinical benefit. Furthermore, analyses of both progression-free survival (PFS) and overall survival (OS) confirmed significantly higher expression levels of immune-related signaling pathways in long-term survivors. Gene expression signatures capable of classifying patients based on clinical response or PFS were also identified. Interestingly, deconvolution analysis revealed a significant higher abundance of resting NK cells in patients with prolonged PFS or OS, in contrast to other cytotoxic cell types. Finally, high expression of the CST7 gene and increased abundance of naïve B lymphocytes were associated with immune-related adverse events (irAE).Conclusions:Total RNA sequencing from whole blood provides high-quality data to predict clinical response, survival, and occurrence of irAE. The use of this type of sample before immune checkpoint blockage could improve treatment efficacy and irAE management.
- Open Access
- 1 April 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S8 from Circulating Transcriptome Analysis Finds Gene Signatures and Immune Cell Activation and Abundance Predict Response to Immunotherapy in Bladder Cancer
Supplementary Figure S8: Gene Set Enrichment Analysis (GSEA) revealed, in patients with longer OS, a significant over-activation of Natural killer cell mediated cytotoxicity, and Cytokine-cytokine receptor interaction pathways. Three other pathways linked to T lymphocytes were also significantly higher expressed in patients with longer OS: T cell receptor signaling pathway, Th1 and Th2 cell differentiation, and Th17 cell differentiation.
- 1 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S8 from Circulating Transcriptome Analysis Finds Gene Signatures and Immune Cell Activation and Abundance Predict Response to Immunotherapy in Bladder Cancer
Supplementary Figure S8: Gene Set Enrichment Analysis (GSEA) revealed, in patients with longer OS, a significant over-activation of Natural killer cell mediated cytotoxicity, and Cytokine-cytokine receptor interaction pathways. Three other pathways linked to T lymphocytes were also significantly higher expressed in patients with longer OS: T cell receptor signaling pathway, Th1 and Th2 cell differentiation, and Th17 cell differentiation.
- Open Access
- 1 April 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from Circulating Transcriptome Analysis Finds Gene Signatures and Immune Cell Activation and Abundance Predict Response to Immunotherapy in Bladder Cancer
Supplementary Figure S5: Gene Set Enrichment Analysis (GSEA) revealed a significant over-activation of 6 KEGG pathways, that could be linked to NK cell activation, in patients with longer PFS: Cytokine-cytokine receptor interaction, Natural killer cell mediated cytotoxicity, Toll-like receptor signaling pathway, Chemokine signaling pathway, IL-17 signaling pathway, and Antigen processing and presentation.
- 1 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from Circulating Transcriptome Analysis Finds Gene Signatures and Immune Cell Activation and Abundance Predict Response to Immunotherapy in Bladder Cancer
Supplementary Figure S5: Gene Set Enrichment Analysis (GSEA) revealed a significant over-activation of 6 KEGG pathways, that could be linked to NK cell activation, in patients with longer PFS: Cytokine-cytokine receptor interaction, Natural killer cell mediated cytotoxicity, Toll-like receptor signaling pathway, Chemokine signaling pathway, IL-17 signaling pathway, and Antigen processing and presentation.
- Open Access
- 1 April 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Circulating Transcriptome Analysis Finds Gene Signatures and Immune Cell Activation and Abundance Predict Response to Immunotherapy in Bladder Cancer
Supplementary Figure S2: Principal Component Analysis revealed that the center of origin was a significant source of variance in the data. Consequently, the center of origin was included as a covariate in all subsequent differential expression analyses to mitigate its impact.
- 1 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Circulating Transcriptome Analysis Finds Gene Signatures and Immune Cell Activation and Abundance Predict Response to Immunotherapy in Bladder Cancer
Supplementary Figure S2: Principal Component Analysis revealed that the center of origin was a significant source of variance in the data. Consequently, the center of origin was included as a covariate in all subsequent differential expression analyses to mitigate its impact.
- Open Access
- 1 April 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S7 from Circulating Transcriptome Analysis Finds Gene Signatures and Immune Cell Activation and Abundance Predict Response to Immunotherapy in Bladder Cancer
Supplementary Figure S7: A. Venn diagram showed that among the 1,204 genes higher expressed in patients with shorter OS, 13 overlapped with genes also higher expressed in patients without DCB and shorter PFS, 5 were in common with genes higher expressed in patients without DCB, 74 overlapped with genes also higher expressed in shorter PFS, and 1,112 were specifically linked to shorter OS. B. Venn diagram showed that among the 631 genes higher expressed in patients with longer OS, 11 overlapped with genes also higher expressed in patients with DCB and longer PFS, 17 overlapped with genes also higher in patients with DCB, 19 were in common with genes higher expressed in patients with longer PFS, and 584 were uniquely related to longer OS.
- 1 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S7 from Circulating Transcriptome Analysis Finds Gene Signatures and Immune Cell Activation and Abundance Predict Response to Immunotherapy in Bladder Cancer
Supplementary Figure S7: A. Venn diagram showed that among the 1,204 genes higher expressed in patients with shorter OS, 13 overlapped with genes also higher expressed in patients without DCB and shorter PFS, 5 were in common with genes higher expressed in patients without DCB, 74 overlapped with genes also higher expressed in shorter PFS, and 1,112 were specifically linked to shorter OS. B. Venn diagram showed that among the 631 genes higher expressed in patients with longer OS, 11 overlapped with genes also higher expressed in patients with DCB and longer PFS, 17 overlapped with genes also higher in patients with DCB, 19 were in common with genes higher expressed in patients with longer PFS, and 584 were uniquely related to longer OS.